Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Stock Information for iCad Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iCad Inc.

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
Arcturus Therapeutics to Attend the Following Investor Conferences
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.